We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

17 hedge funds and large institutions have $2.48M invested in Gyre Therapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

348% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $337K

16% more capital invested

Capital invested by funds: $2.15M → $2.48M (+$333K)

3.24% more ownership

Funds ownership: 0.24% → 3.49% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

37% less funds holding

Funds holding: 27 → 17 (-10)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
17
Holders Change
-10
Holders Change %
-37.04%
% of All Funds
0.42%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
2
Reduced
5
Closed
13
Calls
$1.51M
Puts
$337K
Net Calls
+$1.17M
Net Calls Change
+$1.17M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$312K
2
Simplex Trading
Simplex Trading
Illinois
+$129K
3
BlackRock
BlackRock
New York
+$73.6K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$65.9K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$32.6K

Top Sellers

1
CCM
Colorado Capital Management
Colorado
-$50K
2
IP
Intellectus Partners
California
-$48.5K
3
Goldman Sachs
Goldman Sachs
New York
-$31K
4
VKH
Virtu KCG Holdings
New York
-$25K
5
WS
Wedbush Securities
California
-$24K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
1
Essex Woodlands Management
Texas
$757K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$620K +$312K +5,344 +156%
NMC
3
NEA Management Company
Maryland
$410K – – –
UBS Group
4
UBS Group
Switzerland
$230K -$4.55K -78 -2%
Simplex Trading
5
Simplex Trading
Illinois
$156K +$129K +2,216 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$104K +$32.6K +559 +61%
BlackRock
7
BlackRock
New York
$89K +$73.6K +1,261 New
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$80K +$65.9K +1,128 New
FPF
9
FNY Partners Fund
New York
$26K +$21.8K +373 New
Wells Fargo
10
Wells Fargo
California
$5K +$3.91K +67 New
IP
11
Intellectus Partners
California
$1K -$48.5K -830 -99%
PAM
12
Panagora Asset Management
Massachusetts
$1K – – –
CCM
13
Colorado Capital Management
Colorado
– -$50K -697 Closed
Goldman Sachs
14
Goldman Sachs
New York
– -$31K -430 Closed
VKH
15
Virtu KCG Holdings
New York
– -$25K -340 Closed
WS
16
Wedbush Securities
California
– -$24K -329 Closed
Geode Capital Management
17
Geode Capital Management
Massachusetts
– -$16K -229 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$16K -212 Closed
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$12.2K -209 Closed
TSS
20
Two Sigma Securities
New York
– -$15K -200 Closed
Bank of New York Mellon
21
Bank of New York Mellon
New York
– -$11K -154 Closed
Millennium Management
22
Millennium Management
New York
– -$11K -145 Closed
California Public Employees Retirement System
23
California Public Employees Retirement System
California
– -$9K -119 Closed
ARTA
24
A.R.T. Advisors
New York
– -$6K -92 Closed
Bank of America
25
Bank of America
North Carolina
– -$58 -1 -20%
1
2

GYRE Hedge Fund Activity: Q1 2017 in Review

17 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2017, worth a combined $2.48M — up 16% from $2.15M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of GYRE and 5 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $312K. The largest seller was Colorado Capital Management, exiting entirely with an estimated $50K sold.

  • 17 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2017, down from 27 in Q4 2016.
  • Funds reported $2.48M of Gyre Therapeutics stock for Q1 2017, up 16% quarter-over-quarter.
  • 5 funds opened new Gyre Therapeutics positions in Q1 2017 and 13 closed out, a net change of -8 holders.
  • The largest Gyre Therapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $312K added.
  • The largest Gyre Therapeutics seller in Q1 2017 was Colorado Capital Management, an estimated $50K sold.

Based on aggregated 13F filings for Q1 2017.